PharmaTher Holdings Ltd. announced the commercial launch of its M3DICINES™ platform, which integrates 3D-printed personalized medicines and the CraftMake™ pharmaceutical 3D printer. Initial orders for the CraftMake™ system are planned for Q4 2026, alongside the launch of proprietary 503A peptide products and a ketamine dissolvable tablet for telehealth. The company is targeting orphan drug and rare pediatric disease designations with an NDA submission expected by Q4 2028, potentially earning a valuable priority review voucher. PharmaTher aims to expand into underserved markets including ultra-rare diseases, psychedelics for clinical trials, and discontinued medicines, while building a national emergency network of 3D printing nodes for medical countermeasures. Partnering opportunities and recurring revenue from placements are key to its growth strategy.
PharmaTher's corporate strategy and milestones provide context for readers interested in health sector trends. For readers following health stocks on Pluang as of Oct 05, 2026 18:12 WIB: out of 100 priced US health-sector stocks, 41 rose and 41 fell. Revvity Inc (RVTY) rose 1.30% to USD 153.50 with a typical hold time of 12 days, Cytokinetics Inc (CYTK) increased 1.28% to USD 66.44 with a 19-day hold, while Novo Nordisk A/S (NVO) declined 1.26% to USD 36.85 with a notably longer hold time of 115 days.
SPX Technologies (NYSE: SPXC) recently traded near its 52-week low around $170, down about 1.6% from the previous close. Despite this, several analysts maintain positive outlooks with price targets ranging from $250 to $301, indicating potential upsi...
PBF Energy's shares have surged 173% over the past year, nearing record highs due to stronger refining margins and improved quarterly results. The company reduced its net term debt by over $1.4 billion in Q2 2026, refinanced notes, and maintained nea...
J D Wetherspoon reported an 8.6% increase in like-for-like sales in the first nine weeks of its new financial year, helped by favorable weather. However, profit before tax fell 28% to £58.60 million despite a 5.2% revenue rise to £2.24 billion, mainl...
Oppenheimer has maintained its Outperform rating on Enphase Energy but lowered the price target from $56 to $55. Enphase Energy, a company specializing in solar microinverters, home batteries, and energy management products, has seen its shares drop ...
UBS increased its price target for Ball Corp. from $65 to $66, citing steady demand for packaging products and growth in South America. The stock currently trades at $56.37, implying a potential 17.1% upside. Key factors supporting investor interest ...
